Imeg CKD 500mg Tablet contains Imeglimin, a novel oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus, particularly in patients with chronic kidney disease (CKD). Imeglimin acts by improving mitochondrial function and enhancing insulin secretion while simultaneously reducing hepatic glucose production, thereby addressing multiple pathophysiological defects associated with type 2 diabetes. The 500mg dosage is optimized for efficacy and safety in patients with varying degrees of renal impairment, making it a suitable therapeutic option for glycemic control in CKD stages 3 and 4. Clinical studies have demonstrated that Imeg CKD 500mg effectively lowers HbA1c levels with a favorable safety profile, exhibiting minimal risk of hypoglycemia when used as monotherapy or in combination with other antidiabetic agents. The drug’s mechanism involves modulation of mitochondrial bioenergetics, leading to improved pancreatic β-cell function and insulin sensitivity. Imeg CKD 500mg is administered orally, with dosing adjustments recommended based on renal function to minimize adverse effects. Common side effects may include mild gastrointestinal disturbances, which are generally transient. This medication should be prescribed under medical supervision, with regular monitoring of renal parameters and glycemic control to ensure optimal therapeutic outcomes.